GXO Schedules Second Quarter 2025 Earnings Conference Call for Wednesday, August 6, 2025
GREENWICH, Conn., July 17, 2025 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO) will hold its second quarter 2025 earnings conference call and webcast on Wednesday, August 6, 2025, at 8:30 a.m. Eastern Time. The company's results will be released after market close on Tuesday, August 5, 2025, and made available at that time on investors.gxo.com.
Access information: Call toll-free from U.S./Canada: 877-407-8029International callers: +1 201-689-8029Conference ID: 13754139
Live webcast: investors.gxo.com
A replay of the conference call will be available for approximately two weeks, until August 20, 2025, by calling toll-free (from U.S./Canada) 877-660-6853; international callers dial +1 201‑612‑7415. Use the passcode 13754139.
About GXO Logistics
GXO Logistics, Inc. (NYSE: GXO) is the world's largest pure-play contract logistics provider and is positioned to capitalize on the rapid growth of ecommerce, automation and outsourcing. GXO has more than 150,000 team members across more than 1,000 facilities totaling more than 200 million square feet. The company serves the world's leading blue-chip companies to solve complex logistics challenges with technologically advanced supply chain and ecommerce solutions, at scale and with speed. GXO corporate headquarters is in Greenwich, Connecticut. Visit GXO.com for more information and connect with GXO on LinkedIn, X, Facebook, Instagram and YouTube.
Investor Contact
Kristine Kubacki, CFA+1 203-769-7206
[email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
AIS and Satellite Integration Transforming Marine Radio Systems
The Marine Radio Market, valued at USD 2.4 billion in 2025, is predicted to grow at a CAGR of 8.7%, reaching USD 5.1 billion by 2034. Key drivers include regulatory compliance, digitalization, and growing vessel count. Innovations like AI-integrated, satellite-enabled radios are reshaping maritime communication. Marine Radio Market Dublin, July 30, 2025 (GLOBE NEWSWIRE) -- The "Marine Radio Market Outlook 2025-2034: Market Share, and Growth Analysis By Type (Fixed Mount, Handheld), By Frequency Band Range, By Modulation Technique, By Application" has been added to offering. The Marine Radio Market is projected to expand from a valuation of USD 2.4 billion in 2025, growing at a CAGR of 8.7%, achieving a global sales milestone of USD 5.1 billion by 2034. These crucial communication systems ensure seamless maritime interactions and adhere to strict international safety and navigation laws, covering commercial, recreational, and military vessels, along with offshore platforms. Innovations in marine radios include VHF, MF/HF, satellite models, and advanced AIS integrations, enhancing safety and operational efficiency at sea. Driven by regulatory compliance, the shift towards digital marine operations, and the increasing global vessel count, the market sees potential in compact, multifunctional communications platforms. These developments converge marine radio, radar, and GPS technologies into space-efficient units. The transition from analog to digital systems has been prominent since 2024, particularly in Europe and North America, with DSC-enabled VHF radios becoming the norm for distress signaling and regular communications. Satellite radio systems are gaining popularity for their long-range capabilities, vital for offshore platforms and transoceanic vessels. The introduction of waterproof, AI-integrated radios with voice recognition and real-time data features was notable in recent years. Furthermore, stricter regulations like updated SOLAS protocols demand advanced communication systems from maritime operators. Looking ahead to 2025 and beyond, marine radios are gradually integrating into maritime IoT networks and autonomous vessel systems, featuring intelligent channel management, machine-learning emergency detection, and autonomous interface capabilities. The rise of low-earth orbit (LEO) satellite constellations promises more affordable, widespread satellite radios, providing coverage even in isolated oceanic paths. Innovations in antenna and modular hardware design pave the way for smart bridge system hubs. The emphasis on maritime cybersecurity is increasing demand for encrypted systems, ensuring secure communication on both military and commercial ships. Key Insights: Digital VHF marine radios are rapidly replacing analog versions due to enhanced clarity, automatic distress alerts, and improved interference resistance. Marine radios are increasingly integrated with AIS systems, boosting navigational safety by enabling vessels to broadcast vital data to nearby entities. Demand is rising for compact, multifunctional units combining VHF, GPS, and radar, providing space and cost-efficient solutions for small boats and coastal operators. The adoption of satellite-based systems is growing, benefiting from emerging LEO networks offering swift, economical communication. Advanced, voice-command enabled radios with touchscreen interfaces are being rolled out for high-end vessels, enhancing user experiences under rugged conditions. Global compliance with regulatory mandates from bodies like IMO and SOLAS consistently drives marine radio demand. Fleet expansion, including commercial, recreational, and fishing vessels, broadens the marine radio market scope, notably in the Asia-Pacific and Mediterranean regions. Increased offshore activities necessitate long-range communication solutions like marine radios. Heightened focus on maritime disaster preparedness is driving the push for sophisticated radio systems ensuring safety and emergency readiness. Interference and limited frequency in congested waterways can pose risks, affecting adoption rates in busy port locales. High costs for satellite-based radios may impede upgrades by smaller operators, especially in underfunded regions. Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2025 - 2034 Estimated Market Value in 2025 2.4 Billion Forecasted Market Value by 2034 5.1 Billion Compound Annual Growth Rate 8.7% Regions Covered Global Companies Featured Raytheon Technologies Corporation Thales Group SEA COM Corp. Garmin Ltd. Entel Group JVC Kenwood Holdings Inc. Cobham plc Kongsberg Maritime AS Teledyne FLIR LLC Furuno Electric Co. Ltd. Navico Group Icom Inc. Uniden America Corporation Cobra Electronics Corporation Jotron AS Market Segmentation: By Type: Fixed Mount, Handheld By Frequency Band Range: Low-Band VHF, High-Band VHF, Low-Band UHF, High-Band UHF By Modulation Technique: Amplitude, Frequency, Phase, Spread Spectrum By Application: Fishery, Transport, Leisure, Other For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Marine Radio Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
OTC Markets Group Welcomes PetVivo Holdings Inc. to OTCQX
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced PetVivo Holdings Inc. (OTCQX: PETV), an emerging biomedical device company, has qualified to trade on the OTCQX® Best Market. PetVivo Holdings Inc. upgraded to OTCQX from the OTCQB® Venture Market. PetVivo Holdings Inc. begins trading today on OTCQX under the symbol 'PETV.' U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors. 'Qualifying to trade on the OTCQX Best Market is a significant milestone for our Company,' said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. 'This upgrade reflects our continued commitment to transparency, strong corporate governance, and delivering long-term value to our shareholders. Trading on OTCQX will enhance our visibility within the investment community and provide greater liquidity and accessibility for investors as we continue to execute on our strategic growth initiatives.' About PetVivo Holdings Holdings, Inc. and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo"), are based in Edina, Minnesota. It is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and therapeutics for equine and companion animals. PetVivo believes that it can leverage the investments in the human bio-materials and medical device industries to commercialize medical devices and therapeutics to animals in a capital and time efficient way. PetVivo's strategy is to internally develop and/or in-license proprietary products from human medical device companies specifically for use in pets. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals. PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protects the Company's biomaterials, products, production processes and methods of use. The Company's lead products SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale. For more information about PetVivo Holdings, Inc. please contact info1@ or visit and About OTC Markets Group Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets. OTC Link ATS, OTC Link ECN, OTC Link NQB, and MOON ATS™ are each SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC. To learn more about how we create better informed and more efficient markets, visit Subscribe to the OTC Markets RSS Feed Media Contact:OTC Markets Group Inc., +1 (212) 896-4428, media@
Yahoo
13 minutes ago
- Yahoo
Drug Discovery Platforms Market Size Expected to Reach USD 635.45 Million by 2034
The global drug discovery platforms market size is calculated at USD 211.26 million in 2025 and is expected to reach around USD 635.45 million by 2034, growing at a CAGR of 13.44% for the forecasted period. Ottawa, July 30, 2025 (GLOBE NEWSWIRE) -- The global drug discovery platforms market size was valued at USD 186.24 million in 2024 and is predicted to hit around USD 635.45 million by 2034, a study published by Towards Healthcare a sister firm of Precedence Research. The growth of the market is driven by the growing investments in research and development, and integration of AI and ML with technological advancements further drives the growth of the market. Get a free sample of the Drug Discovery Platforms Market report to preview key insights and trends: Key Takeaways North America dominated the global drug discovery platforms market in 2024. Asia-Pacific is anticipated to grow at the fastest rate in the market during the forecast period. By type of display library technology, the phage display segment held a dominant presence in the market in 2024. By type of display library technology, the yeast display segment is anticipated to grow at the fastest rate in the market during the studied years. By type of molecule, the antibodies segment dominated and was observed to sustain the dominance over the forecast period. Drug Discovery Platforms Market Overview & Potential Drug discovery platforms are integrated systems designed to streamline and speed up the process of finding, developing, and refining potential drug candidates. They utilize technologies such as artificial intelligence (AI), high-throughput screening, and automation to identify promising targets and molecules. These platforms aim to enhance efficiency, cut costs, and accelerate drug development compared to traditional methods. They are transforming the pharmaceutical industry by speeding up the creation of new, effective medicines. By integrating advanced technologies and simplifying the discovery process, these platforms are set to play a vital role in future healthcare advancements. What is the Growth Potential Responsible for the Growth of the Drug Discovery Platforms Market? The global market for drug discovery platforms is growing rapidly, fueled by several key factors. These include rising rates of chronic and infectious diseases, increasing investment in pharmaceutical and biotech R&D, and technological advances like AI, machine learning, and high-throughput screening. Additionally, the focus on precision medicine and targeted therapies is expanding the market. The use of drug discovery platforms is also broadening beyond traditional pharma research to include biotech, diagnostics, and personalized medicine, further boosting growth. You can place an order or ask any questions, please feel free to contact us at sales@ What Are the Growing Trends Associated with the Drug Discovery Platforms Market? AI-powered Drug Discovery: AI is transforming drug discovery by speeding up research, increasing accuracy, and shortening development timelines. It is used in target identification, molecule design, and optimizing clinical trials. Cloud-based Platforms: Cloud computing is becoming essential in drug discovery, offering benefits like streamlined operations, lower costs, and quicker development cycles. Display Libraries: Display libraries, especially phage display, are gaining popularity for their ability to enable large-scale, high-throughput screening and increase diversity in lead discovery. Precision Medicine: Interest in precision medicine and targeted therapies is growing, with researchers aiming to develop drugs tailored to specific patient groups and disease types. What Is the Growing Challenge in the Drug Discovery Platforms Market? The drug discovery platforms market faces hurdles such as rising costs, long development times, and difficulties in accurately modeling disease mechanisms. Other issues include data privacy concerns, cybersecurity threats, and the need for skilled personnel to operate AI-based systems. These factors hinder the growth of the market and limit its expansion of the market. The government support, large patient population, growing CROs, cost effectiveness, strategic partnerships, AI and informatics, visual drug discovery services, and drug repurposing further fuel the growth and expansion of the market in the region. Get the latest insights on life science industry segmentation with our Annual Membership: Regional Analysis How Did North America Dominate the Drug Discovery Platforms Market in 2024? North America dominated the global drug discovery platforms market in 2024. The growth of the market in the region is driven by the well-established infrastructure, especially healthcare infrastructure, along with rising investment for research and development by the government, also further fuels the growth of the market in the region. The strong presence of pharmaceutical and biotechnology companies in the region also increases the demand for the market due to growing research for drug discovery and development, which further fuels the growth of the market. The supportive regulatory environment and increased research and development spending by pharmaceutical and biotech companies in the region further fuel the growth of the market in the region. The U.S. fosters drug discovery platforms market growth through strong academic-industry collaboration, advanced biotech infrastructure, and a robust intellectual property system. Government initiatives and regulatory support encourage innovation. A rich talent pool from leading universities drives research, while access to venture capital enables startups and established firms to advance novel therapies efficiently. Canada supports drug discovery through significant public funding, academic partnerships, and a collaborative research environment. Institutions emphasize translational medicine and early-stage R&D. Regulatory agencies encourage innovation with progressive frameworks. The country's multicultural population also enables diverse clinical research, strengthening Canada's role in addressing global health challenges through targeted drug development. What Made the Asia Pacific Significantly Grow in The Drug Discovery Platforms Market In 2024? Asia-Pacific is anticipated to grow at the fastest rate in the market during the forecast period. Increased government investments in pharmaceutical research and infrastructure development through government support propel the growth of the market in the region. The rising healthcare expenditure leads to greater demand for advanced healthcare solutions also increases the growth of the market. Asia Pacific is a growing and emerging hub for contract research organizations play a crucial role in outsourcing drug discovery activities by other regions' consumers, driving the growth of the market in the region. Government reforms, talent repatriation, and investment in life sciences drive China's expanding drug discovery platforms market. Research parks and biotech hubs across cities like Shanghai promote innovation. Enhanced regulatory processes and incentives for novel drug development have shifted the focus from generics to original therapeutics, boosting domestic pharmaceutical innovation. India's growth in drug discovery stems from its vast scientific workforce, cost-effective research capabilities, and strong academic institutions. Government initiatives support innovation through incubators and biotech parks. Rising collaboration between academia and industry fosters early-stage research, while improvements in regulatory frameworks encourage the development of original molecules and targeted therapies. According to Volza's Global Export data, the World shipped out 248122 Pharmaceutical shipments from November 2023 to October 2024 (TTM). These exports were handled by 7224 global exporters to 12066 buyers, showing a growth rate of 133% over the previous 12 months. Globally, India, Belgium, and the United States are the top three exporters of pharmaceuticals. India is the global leader in Pharmaceutical exports with 578683 shipments, followed closely by Belgium with 9244 shipments, and the United States in third place with 8465 shipments. Elevate your healthcare strategy with Towards Healthcare. Enhance efficiency and drive better outcomes schedule a call today: Segmental Insights By Type of Display Library Technology The phage display segment held a dominant presence in the drug discovery platforms market in 2024. The phase display is a key technology that is used in drug discovery to isolate and identify the desired molecule, especially proteins and peptides, that bind to the target molecule. The key advantages of phase displays, like high diversity, versatility, and efficiency, further increase the demand for the market. The application in drug discovery, like antibody discovery, peptide therapeutics, target validation, and vaccine development, boosts the growth of the market. The growing key therapeutic applications, like the development of therapeutic antibodies, propel the demand for the market, further contributing to the expansion of the market. The yeast display segment is anticipated to grow at the fastest rate in the drug discovery platforms market during the studied years. The growth of the market is driven by the growing applications like antibody discovery, enzyme engineering, protein-protein interaction studies, target-based drug discovery, and nanobody discovery increases the demand for the technology, which fuels the growth of the market. The growing advantages and properties offered by the technology, like quantitative analysis, compatibility with FACS, affinity maturation, high throughput screening, and eukaryotic systems, play a crucial role in further propelling the growth and expansion of the market. By Type Of Molecule The antibodies segment dominated and was observed to sustain the dominance over the forecast period. The antibodies segment holds a significant share in the drug discovery platform market, driven by the growing use of monoclonal and polyclonal antibodies in targeted therapies. These molecules are widely used in immunotherapy, oncology, and autoimmune disease treatment due to their high specificity and efficacy. Drug discovery platforms support antibody screening, engineering, and optimization, accelerating development timelines. As demand for biologics continues to rise, the adoption of advanced platforms for antibody discovery fuels market growth in this segment. Recent Developments in the Drug Discovery Platforms Market In July 2025, Elix and the Life Intelligence Consortium (LINC) announced the commercial launch of an AI-based drug discovery platform that uses federated learning across data from multiple pharmaceutical companies. This marks the first global deployment of such technology. In March 2025, Boehringer Ingelheim introduced its new comprehensive technology platform on Tuesday, aimed at streamlining data management and processes to accelerate drug development. The One Medicine Platform will replace over 20 outdated systems, creating a unified ecosystem to improve cross-functionality and operational efficiency. Top Companies and Their Contributions to the Market Company Contributions & Offerings Insilico Medicine Leverages - PandaOmics for AI-powered target/biomarker discovery, Chemistry42 for generative molecule design, and InClinico for clinical trial prediction. Has taken its lead pan-fibrotic candidate, INS018_055, from target discovery to Phase II in ~30 months. Demonstrated bioavailable CDK8 inhibitor via AI-driven Chemistry42. Evotec Offers end-to-end integrated drug discovery: target ID, screening, medicinal chemistry, biologics manufacturing, and CMC. Partners include Janssen (via TargetAlloMod), Lilly (metabolic/kidney diseases), Novartis, Novo Nordisk, Related Sciences, and more, powering multi-modality pipelines. Laboratory Corporation of America Holdings (LabCorp) Provides high-throughput pre-clinical screening, biomarker profiling, ADME/Tox, clinical trial diagnostics, and real-world evidence solutions. Integrates genomics, data analytics, and centralized labs globally to accelerate translational and clinical R&D. Atomwise Uses deep learning and structure-based AI (AtomNet) to predict protein–ligand binding, enabling virtual high-throughput screening on millions of compounds, partners with pharma and biotech to identify lead molecules for diverse therapeutic targets. Merck Owns Merck Research Labs with integrated in-house platforms including computational chemistry, high-throughput screening, and genomics. It invests in AI collaborations (e.g., with Schrödinger, Cyclica) to bolster target identification and small-molecule discovery. Pfizer Builds extensive discovery platforms—HTS, structural biology, chemoinformatics, AI/ML modeling, and phenotypic screening. Active in AI drug discovery partnerships (e.g., XtalPi, DeepMind), and open science efforts for protein structure and drug-target mapping. Exscientia plc Pioneers AI-driven end-to-end drug design, advancing candidate molecules into clinical trials faster via Centaur Chemist. Publishes human-dose candidates from AI design, with strategic pharma partnerships and a pipeline in immuno-oncology and cardiometabolic diseases. Thermo Fisher Scientific Supplies essential platforms: high-throughput screening systems, mass spectrometry, protein analysis, cell-based assays, informatics software, and reagent kits. Supports discovery across small molecules, biologics, and cell therapies via integrated hardware and software solutions. Recursion Pharmaceuticals Combines automated biology (cell imaging) with AI/ML to rapidly characterize disease models and drug effects. Progressed eight AI-designed drug candidates (REC-3565, REC-994, etc.) into clinical trials. Offers Recursion OS, enabling biology-first target discovery. Eli Lilly and Company Maintains Lilly Research Labs with integrated capabilities: high-throughput screening, structural biology, computational chemistry, and translational biomarkers. Partners with AI-first firms (e.g., with Evotec, Insilico) to accelerate novel therapeutic target discovery and drug design. Browse More Insights of Global Drug Discovery & Development The GLP-1 drugs market is witnessing rapid momentum worldwide, with expectations of generating substantial revenue potentially in the hundreds of millions between 2025 and 2034. The global immuno-oncology drugs market is on a high-growth trajectory. Valued at US$ 94 billion in 2024, it is projected to reach US$ 109.39 billion in 2025 and soar to approximately US$ 421.27 billion by 2034, growing at a CAGR of 16.34% over the forecast period. The U.S. drug screening market is steadily growing. From US$ 2.70 billion in 2024 to US$ 2.79 billion in 2025, it's expected to reach US$ 3.84 billion by 2034, expanding at a CAGR of 3.64%. The computer-aided drug design (CADD) market is gaining traction globally, with anticipated revenues climbing into the hundreds of millions over the next decade. The drug discovery SaaS platforms market is evolving fast, expected to generate significant revenue between 2025 and 2034 as digital transformation accelerates across pharma R&D. The drug discovery as a service market is expanding rapidly from US$ 21.3 billion in 2024 to US$ 24.32 billion in 2025, and is forecasted to reach US$ 79.82 billion by 2034, growing at a CAGR of 14.17%. The generative AI in drug discovery market is making waves. Valued at US$ 250 million in 2024, it's set to grow to US$ 318.55 million in 2025, and nearly US$ 2.85 billion by 2034, posting an impressive CAGR of 27.42%. The machine learning in drug discovery market is experiencing a notable surge, with revenues expected to reach several hundred million dollars by 2034, reflecting growing adoption across the pharmaceutical value chain. Similarly, the AI and ML in drug development market is rapidly expanding worldwide, with strong potential for multimillion-dollar revenues throughout the forecast period. The sterile drug product testing market is on a growth path driven by rising production of biologics and injectable drugs, making it a key segment to watch from 2024 to 2034. Drug Discovery Platforms Market Key Players Insilico Medicine Evotec Laboratory Corporation of America Holdings Atomwise Merk Pfizer Exscientia plc Thermo Fisher Recursion Pharmaceuticals Eli Lilly and Company Roche Segments Covered in The Report By Type of Display Library Technology Phage display library Yeast display Other By Type of Molecule Antibodies Peptides Other By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Access the complete Drug Discovery Platforms Market report for in-depth analysis, forecasts, and strategic recommendations: You can place an order or ask any questions, please feel free to contact us at sales@ Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | InstagramSign in to access your portfolio
